Navigation Links
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Date:8/14/2008

PRINCETON, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the third fiscal quarter ended June 30, 2008. Pharmasset reported a net loss attributable to common stockholders of $15.0 million, or a loss per share of $0.69 for the quarter ended June 30, 2008, as compared to a net loss attributable to common stockholders of $7.1 million, or a loss per share of $0.40 per share for the same period in 2007.

Revenues were $0.5 million during the quarters ended June 30, 2008 and 2007 and reflect amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue. Total costs and expenses for the quarter ended June 30, 2008 were $15.0 million, as compared to $7.1 million for the same period in 2007. The $7.9 million increase in total costs and expenses during the quarter ended June 30, 2008 was primarily due to a $5.8 million increase in Phase 3 clinical trial expenses to support registration of clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.0 million increase in compensation expense resulting from increased headcount, a $0.4 million increase in new drug discovery expenses, and a $0.7 million increase in marketing and other administrative expenses. Investment income decreased to $0.2 million during the quarter ended June 30, 2008 from $0.7 million in the quarter ended June 30, 2007, primarily on lower rates of return on invested balances. Interest expense increased to $0.7 million during the quarter ended June 30, 2008 from $0.0 million in the yea
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmasset Receives Notice of Allowance
4. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
5. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
6. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Research and ... "Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The purpose of this ... for Disposable Medical (Exam and Surgical) Gloves. The report ... for these products. Topics covered include product ...
(Date:7/23/2014)... 2014  Nearly 8,000 attendees will converge in ... Retail Business Conference (RBC), taking place July 23-26 at ... event encourages pharmacists to "Lead Change" in the pharmacy ... for their future. "RBC is the ... their peers and learn new ways they can lead ...
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... BURLINGTON, Vt ., June 4 Mach 7 Technologies ... has relocated its global headquarters from suburban Chicago to ... the company,s base for Americas, sales and professional service operations, and ... and strategic R&D functions. , ...
... June 4 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) ... China , today,announced that the Company has received approval to list its ... , , ... will begin trading on the NASDAQ,Global Market on Tuesday, June 8, ...
Cached Medicine Technology:Mach 7 Technologies Establishes New Headquarters in Burlington, VT 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 3
(Date:7/23/2014)... The National Quality Forum’s (NQF) Board ... for a defined period that will assess the ... measures for sociodemographic factors, prior to making a ... can be socioeconomic, e.g., income, education, and occupation, ... Growing evidence shows that sociodemographic factors may ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... Steven Reinberg HealthDay ... -- Many obese and overweight American children and teens ... is fine, U.S. health officials reported Wednesday. "Being ... such as high blood pressure, high cholesterol and diabetes," ... the U.S. Centers for Disease Control and Prevention,s National ...
(Date:7/23/2014)... Inventor and entrepreneur Delegate Joe T. ... the gas pump – sharing his passion for technology ... at Noon. , With 24 patents granted and three ... anyone in the General Assembly since Thomas Jefferson. Inventions ... marker as seen on television, an instrument for measuring ...
(Date:7/23/2014)... WHAT: The National Institute of Biomedical Imaging and ... Investigator Symposium on July 30, 2014 on the NIH ... new investigators covering a wide breadth of NIBIB-funded research. ... Adam Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage ... Testing Fluorescently Labeled Probes for Nerve ...
Breaking Medicine News(10 mins):Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
... UK, US and Canada are undermining tobacco prevention campaigns by ... public health researchers says. The paper, published in the open ... tobacco imagery should be ineligible for public funding to ensure ... goals. Earlier research shows that young people who are ...
... Aug. 23 (HealthDay News) -- Researchers say boys are ... that males have been reaching sexual maturity about 2.5 ... "The reason for earlier maturity for ... disease environments are getting more favorable for it," demographer ...
... 2011 In a joint research effort with researchers ... from scientists at The University of Pennsylvania, The University ... from the Florida campus of The Scripps Research Institute ... to rid themselves of damaged mitochondria, which are the ...
... in a new study a different approach to predict ... other similar chemicals. For many chemicals in ... to understand all of the effects on the environment ... Union enacted the REACH regulation, which places greater responsibility ...
... the University of Toronto,s psychology department show that ... Botox injections or surgery are viewed more negatively than ... facial creams and younger adults are more negative about ... suggest that despite the rapid growth of the anti-aging ...
... most frequent type of malignant brain tumor in children. Ependymoma ... hollow cavities of the brain. Therapy results of ependymoma vary ... standstill after surgery and radiotherapy, in other children the disease ... affected the tumor continues to grow and the patients often ...
Cached Medicine News:Health News:Government subsidies to the US film industry promote youth smoking, argue researchers 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Scripps Research scientists define cellular pathway essential to removing damaged mitochondria 2Health News:Scientists develop new approaches to predict the environmental safety of chemicals 2Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Brain tumors found to have a 2-tier system 2
Round handle colibri tying forceps with 5 mm titanium coated platforms. Length 100 mm....
Barraquer straight tying forceps....
Round handle curved tying forceps with 5 mm titanium coated platforms. Length 110 mm....
Colibri tying forceps with 5 mm titanium coated platforms. Length 85 mm....
Medicine Products: